<DOC>
	<DOCNO>NCT01876745</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate safety efficacy NovoSeven® ( activate recombinant factor VII , eptacog alfa ( activate ) ) bleed episodes prevention bleed surgery/delivery patient Glanzmann 's thrombasthenia ( GT ) /Glanzmann 's disease .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy NovoSeven® Patients With Glanzmann 's Thrombasthenia Japan</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Informed consent obtain studyrelated activity ( Study relate activity procedure relate recording data accord protocol ) . Alltreated patient registration period Known suspect allergy study product ( ) relate product Septicaemia ( especially , septicaemia follow severely infected patient cause gramnegative bacteria [ The risk DIC ( disseminate intravascular coagulation ) cause endotoxemia could deny ] Patients history hypersensitivity product component</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>